Subsys sales almost triple for Insys

|About: Insys Therapeutics, Inc. (INSY)|By:, SA News Editor

Insys Therapeutics (INSY +4.5%) Q2 results: Revenues: $55.7M (+196.3%); Operating Expenses: $34.0M (+209.1%); Net Income: $9.5M (+108.2%); EPS: $0.26 (+52.9%); Quick Assets: $54.7M (+19.4%).

Subsys (fentanyl sublingual spray) sales: $54.6M (+195.1%).

No financial guidance given.